keyword
MENU ▼
Read by QxMD icon Read
search

treatment of schizophrenia

keyword
https://www.readbyqxmd.com/read/29165095/metabolic-syndrome-and-cardiovascular-risk-in-people-treated-with-long-acting-injectable-antipsychotics
#1
Vanessa Sanchez-Martinez, Dolores Romero-Rubio, Maria Jose Abad-Perez, Maria Amparo Descalzo-Cabades, Sofia Alonso-Gutierrez, Jose Salazar-Fraile, Vicente Montagud, Lorenzo Facila
BACKGROUND: People with schizophrenia and other severe mental disorders have an increased mortality mainly attributed to natural causes, specifically cardiovascular disease and cancer. The metabolic syndrome and the Framingham Risk Score are epidemiologic tools related to long-term cardiovascular disease risk and they are increased in people with severe mental disorders. This increase has been attributed both to the disorder itself and to the use of antipsychotic drugs. OBJECTIVE: To quantify the cardiovascular risk in a group of people treated with long-acting injectable antipsychotics...
November 20, 2017: Endocrine, Metabolic & Immune Disorders Drug Targets
https://www.readbyqxmd.com/read/29165075/preferential-formulation-of-second-generation-antipsychotic-asenapine-as-inclusion-complex-with-sulphobutylether-%C3%AE-cd-captisol-in-vitro-and-in-vivo-evaluation
#2
Amelia Makarand Avachat, Juilee A Kulkarni, Charul M Avachat, Rohan Pradhan, Tushar S Suryawanshi, E M Khan, Elvis A F Martis, Evans C Coutinho, Subhash Padhye
Asenapine is an anti-psychotic agent approved by the US-FDA for treatment of acute schizophrenia and manic or bipolar I disorder in adults. It is poorly absorbed when administered orally, hence exhibits poor oral bioavailability, which limits its use in clinical practice. Consequently, enhancement in its solubility through complexation with three different cyclodextrins, viz. βCD (β cyclodextrin), HPβCD (Hydroxypropyl β cyclodextrin) and sulphobutylether-βCD (Captisol®) was attempted and compared. Kneading method was used for preparation of inclusion complexes which were characterized by FTIR, DSC, and XRD methods...
November 20, 2017: Current Drug Delivery
https://www.readbyqxmd.com/read/29164927/a-case-of-a-patient-with-residual-symptoms-of-schizophrenia-who-relapsed-following-treatment-with-the-topical-corticosteroid-clobetasol-a-review-of-its-risk-of-systemic-absorption-and-possibility-of-exacerbating-psychosis
#3
David R Spiegel, Umer Arsani, Stephanie Le
Almost fifty percent of patients with schizophrenia experience some type of dermatitis. The standard treatment for dermatitis is a topical corticosteroid. Despite their demonstrated effectiveness, topical corticosteroids are associated with various side effects that may limit their use. These include generalized adverse effects from systemic absorption, such as suppression of the hypothalamic-pituitary-adrenal axis. While dose-related, oral corticosteroid-induced psychiatric symptoms, such as psychosis, are well documented, the literature is devoid of cases of topical corticosteroids precipitating psychosis...
November 22, 2017: Clinical Schizophrenia & related Psychoses
https://www.readbyqxmd.com/read/29164787/factors-related-to-duration-of-untreated-psychosis-of-first-episode-schizophrenia-spectrum-disorder
#4
Yong Qiu, Leijun Li, Zhaoyu Gan, Jihui Wang, Liangrong Zheng, Jiaoshi Zhao, Nianhong Guan, Qinling Wei
AIM: Duration of untreated psychosis (DUP) is associated with outcome and functioning. It is expected that scientists will find factors that modulate DUP, but thus far, research on this topic has shown inconsistent results. Furthermore, similar studies in China are insufficient. This study aims to explore social and clinical factors for DUP in South China and to learn the influence that family plays on DUP through their awareness of psychosis. METHODS: Participants included 216 patients with first episode schizophrenia spectrum disorder...
November 22, 2017: Early Intervention in Psychiatry
https://www.readbyqxmd.com/read/29164477/genetic-variants-within-molecular-targets-of-antipsychotic-treatment-effects-on-treatment-response-schizophrenia-risk-and-psychopathological-features
#5
Marco Calabrò, Stefano Porcelli, Concetta Crisafulli, Sheng-Min Wang, Soo-Jung Lee, Changsu Han, Ashwin A Patkar, Prakash S Masand, Diego Albani, Ilaria Raimondi, Gianluigi Forloni, Sofia Bin, Carlotta Cristalli, Vilma Mantovani, Chi-Un Pae, Alessandro Serretti
Schizophrenia (SCZ) is a common and severe mental disorder. Genetic factors likely play a role in its pathophysiology as well as in treatment response. In the present study, we investigated the effects of several single nucleotide polymorphisms (SNPs) within 9 genes involved with antipsychotic (AP) mechanisms of action. Two independent samples were recruited. The Korean sample included 176 subjects diagnosed with SCZ and 326 healthy controls, while the Italian sample included 83 subjects and 194 controls. AP response as measured by the positive and negative syndrome scale (PANSS) was the primary outcome, while the secondary outcome was the SCZ risk...
November 21, 2017: Journal of Molecular Neuroscience: MN
https://www.readbyqxmd.com/read/29163982/individual-differences-in-schizophrenia
#6
Edmund T Rolls, Wenlian Lu, Lin Wan, Hao Yan, Chuanyue Wang, Fude Yang, Yunlong Tan, Lingjiang Li, Hao Yu, Peter F Liddle, Lena Palaniyappan, Dai Zhang, Weihua Yue, Jianfeng Feng
Background: Whether there are distinct subtypes of schizophrenia is an important issue to advance understanding and treatment of schizophrenia. Aims: To understand and treat individuals with schizophrenia, the aim was to advance understanding of differences between individuals, whether there are discrete subtypes, and how first-episode patients (FEP) may differ from multiple episode patients (MEP). Method: These issues were analysed in 687 FEP and 1880 MEP with schizophrenia using the Positive and Negative Syndrome Scale for (PANSS) schizophrenia before and after antipsychotic medication for 6 weeks...
November 2017: BJPsych Open
https://www.readbyqxmd.com/read/29163244/peripheral-transcription-of-nrg-erbb-pathway-genes-are-upregulated-in-treatment-resistant-schizophrenia
#7
Md Shaki Mostaid, Ting Ting Lee, Gursharan Chana, Suresh Sundram, Cynthia Shannon Weickert, Christos Pantelis, Ian Everall, Chad Bousman
Investigation of peripheral gene expression patterns of transcripts within the NRG-ErbB signaling pathway, other than neuregulin-1 (NRG1), among patients with schizophrenia and more specifically treatment-resistant schizophrenia (TRS) is limited. The present study built on our previous work demonstrating elevated levels of NRG1 EGFα, EGFβ, and type I(Ig2) containing transcripts in TRS by investigating 11 NRG-ErbB signaling pathway mRNA transcripts (NRG2, ErbB1, ErbB2, ErbB3, ErbB4, PIK3CD, PIK3R3, AKT1, mTOR, P70S6K, eIF4EBP1) in whole blood of TRS patients (N = 71) and healthy controls (N = 57)...
2017: Frontiers in Psychiatry
https://www.readbyqxmd.com/read/29163233/symptom-overlap-and-screening-for-symptoms-of-attention-deficit-hyperactivity-disorder-and-psychosis-risk-in-help-seeking-psychiatric-patients
#8
Salvatore Corbisiero, Anita Riecher-Rössler, Jacqueline Buchli-Kammermann, Rolf-Dieter Stieglitz
Symptoms of attention-deficit/hyperactivity disorder (ADHD) and psychosis risk share features which might represent an early vulnerability marker for schizophrenia. Early detection of individuals with this symptomatic overlap is relevant and may assist clinicians in their decision making for diagnosis and treatment. This study sought to analyze the capability of different instruments in the screening of patients for ADHD symptoms or at psychosis risk, assess their classification accuracy, and describe the extent of symptoms overlap between them...
2017: Frontiers in Psychiatry
https://www.readbyqxmd.com/read/29162032/the-metabolic-side-effects-of-12-antipsychotic-drugs-used-for-the-treatment-of-schizophrenia-on-glucose-a-network-meta-analysis
#9
Yangyu Zhang, Yingyu Liu, Yingying Su, Yueyue You, Yue Ma, Guang Yang, Yan Song, Xinyu Liu, Mohan Wang, Lili Zhang, Changgui Kou
BACKGROUND: Antipsychotics have serious metabolic side effects on blood glucose. However, the comparative influence of these drugs on blood glucose levels has not been comprehensively evaluated. We conducted a network meta-analysis to create a hierarchy of the side effects of 12 antipsychotic drugs on changes in blood glucose levels. METHODS: A systematic search of the PubMed, EMBASE and Cochrane databases (last search June 2016) was conducted to identify studies that reported randomized controlled trials (RCTs) comparing changes in blood glucose levels between patients receiving one of 12 antipsychotic drugs or a placebo for the treatment of schizophrenia or related disorders...
November 21, 2017: BMC Psychiatry
https://www.readbyqxmd.com/read/29161951/an-open-treatment-six-week-study-of-the-clinical-effectiveness-of-paliperidone-palmitate-in-schizophrenia-data-from-acute-units-in-spain-shadow-study
#10
Eduard Parellada, Miquel Bioque, Manuel Serrano, Berta Herrera, Marta García Dorado
OBJECTIVES: To evaluate clinical evolution of patients with schizophrenia admitted in acute units because of a relapse and treated with once-monthly Paliperidone Palmitate (PP1M). METHODS: This multicentre, open-label, prospective observational study followed patients with schizophrenia treated with PP1M in acute psychiatric units for up to 6 weeks. RESULTS: Out of the 280 enrolled patients, 61 received PP1M as antipsychotic monotherapy, and 219 in combination with other antipsychotics...
November 21, 2017: International Journal of Psychiatry in Clinical Practice
https://www.readbyqxmd.com/read/29161150/cognitive-impairment-in-schizophrenia-and-depression-a-comparison-of-stability-and-course
#11
Peter Neu, Tina Gooren, Ulrike Niebuhr, Peter Schlattmann
Cognitive deficits are clinically relevant features in schizophrenia and depression, yet little comparative data on changes in both disorders is available. This study compares cognitive performance of inpatients with schizophrenia (N = 52) and unipolar major depression (N = 67) during psychiatric treatment, assessing performance twice: after admission to hospital (acute) and prior to discharge (postacute) on average seven weeks later. A group of healthy controls was tested at comparable intervals. Data was analyzed using a multivariate linear model...
November 21, 2017: Applied Neuropsychology. Adult
https://www.readbyqxmd.com/read/29160620/dna-methylation-of-mb-comt-in-malaysian-schizophrenia-patients
#12
Abd Rahim Nour El Huda, Ku Zaifah Norsidah, Rahim Mohd Nabil Fikri, Mohd Noor Hanisah, Abdullah Kartini, A Talib Norlelawati
AIM: This study examined catechol-O-methyltransferase (COMT) DNA methylation in the peripheral blood of schizophrenia patients and also in healthy controls to investigate its potential use as a peripheral biomarker of schizophrenia and its relationships with the clinical variables of schizophrenia patients. METHODS: We examined the DNA methylation levels of COMT using genomic DNA from the peripheral blood of schizophrenia patients (n = 138) and healthy control participants (n = 132); all were Malaysian Malays...
November 21, 2017: Psychiatry and Clinical Neurosciences
https://www.readbyqxmd.com/read/29159134/model-selection-and-prediction-of-outcomes-in-recent-onset-schizophrenia-patients-who-undergo-cognitive-training
#13
Ian S Ramsay, Sisi Ma, Melissa Fisher, Rachel L Loewy, J Daniel Ragland, Tara Niendam, Cameron S Carter, Sophia Vinogradov
Predicting treatment outcomes in psychiatric populations remains a challenge, but is increasingly important in the pursuit of personalized medicine. Patients with schizophrenia have deficits in cognition, and targeted cognitive training (TCT) of auditory processing and working memory has been shown to improve some of these impairments; but little is known about the baseline patient characteristics predictive of cognitive improvement. Here we use a model selection and regression approach called least absolute shrinkage and selection operator (LASSO) to examine predictors of cognitive improvement in response to TCT for patients with recent onset schizophrenia...
March 2018: Schizophrenia Research. Cognition
https://www.readbyqxmd.com/read/29158676/role-of-3-monthly-long-acting-injectable-paliperidone-in-the-maintenance-of-schizophrenia
#14
REVIEW
Claudio Brasso, Silvio Bellino, Paola Bozzatello, Cristiana Montemagni, Paola Rocca
Aims: Paliperidone palmitate 3-month (PP3M) represents a new long-acting injectable antipsychotic therapeutic option. This review aims: 1) to summarize available data relating to efficacy, safety, tolerability and costs of PP3M; 2) to describe hospitalization rate, occupational status, treatment preference, satisfaction, adherence and caregiver burden of patients with schizophrenia who participate in PP3M clinical trials; 3) to examine ethical implications, pros and cons of PP3M use and 4) to propose study designs to further assess PP3M...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/29158012/a-randomized-double-blind-placebo-controlled-proof-of-concept-study-to-evaluate-samidorphan-in-the-prevention-of-olanzapine-induced-weight-gain-in-healthy-volunteers
#15
Bernard L Silverman, William Martin, Asli Memisoglu, Lauren DiPetrillo, Christoph U Correll, John M Kane
Antipsychotic medications are associated with weight gain and adverse metabolic effects that complicate the treatment and management of schizophrenia. Olanzapine (OLZ) in particular is associated with significant weight gain and adverse metabolic effects. The present Phase 1, proof of concept, multicenter, randomized, double-blind, placebo-controlled study investigated the safety and effect on weight of a combination of OLZ (10mg) and the opioid modulator samidorphan (SAM; 5mg) in comparison to OLZ alone in healthy, male normal weight volunteers...
November 17, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/29156812/correlation-of-drd2-mrna-expression-levels-with-deficit-syndrome-severity-in-chronic-schizophrenia-patients-receiving-clozapine-treatment
#16
Liang Liu, Yin Luo, Guofu Zhang, Chunhui Jin, Zhenhe Zhou, Zaohuo Cheng, Guozhen Yuan
Schizophrenia is a complex, severe, chronic psychiatric disorder, and the associated deficit syndrome is widely regarded as an important clinical aspect of schizophrenia. This study analyzed the relationship of deficit syndrome severity with the mRNA levels of members of signaling pathways that associate with the pathophysiology of schizophrenia, including the dopamine D2 receptor (DRD2), protein kinase B (AKT1), and phosphoinositide-3 kinase (PI3KCB), in peripheral blood leukocytes (PBLs) of 20 healthy controls and 19 chronic schizophrenia patients with long-term clozapine treatment...
October 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29155259/polyi-c-model-of-schizophrenia-in-rats-induces-functional-brain-changes-detected-by-mri-irreversible-by-aripiprazole-treatment
#17
Eva Drazanova, Jana Ruda-Kucerova, Lucie Kratka, Katerina Horska, Regina Demlova, Zenon Starcuk, Tomas Kasparek
BACKGROUND AND PURPOSE: One of the hallmarks of schizophrenia is altered brain structure, potentially due to antipsychotic treatment, the disorder itself or both. It was proposed that functional changes may precede the structural ones. In order to understand and potentially prevent this unwanted process, brain function assessment should be validated as a diagnostic tool. METHODS: We used Arterial Spin Labelling MRI technique for the evaluation of brain perfusion in several brain regions in a neurodevelopmental poly(I:C) model of schizophrenia (8 mg/kg on a gestational day 15) in rats taking into account sex-dependent effects and chronic treatment with aripiprazole (30 days), an atypical antipsychotic acting as a partial agonist on dopaminergic receptors...
November 16, 2017: Brain Research Bulletin
https://www.readbyqxmd.com/read/29154107/aripiprazole-in-treatment-of-gilles-de-la-tourette-syndrome-new-therapeutic-option
#18
REVIEW
Piotr Janik, Natalia Szejko
Aripiprazole is a dopamine D2- and serotonin 5-hydroxytryptamine (5-HT)1A receptor partial agonist and 5-HT2A receptor antagonist primarily used for the treatment of schizophrenia, bipolar disorder or depression with psychotic ideation. However, recently a number of new possible indications have been suggested, among them Gilles de la Tourette syndrome (GTS). In two randomized, double-blind, placebo-controlled studies in children and adolescents with GTS has been confirmed the efficacy of aripiprazole in tic reduction...
November 9, 2017: Neurologia i Neurochirurgia Polska
https://www.readbyqxmd.com/read/29153447/abnormal-brain-activation-during-threatening-face-processing-in-schizophrenia-a-meta-analysis-of-functional-neuroimaging-studies
#19
Debo Dong, Yulin Wang, Xiaoyan Jia, Yingjia Li, Xuebin Chang, Marie Vandekerckhove, Cheng Luo, Dezhong Yao
Impairment of face perception in schizophrenia is a core aspect of social cognitive dysfunction. This impairment is particularly marked in threatening face processing. Identifying reliable neural correlates of the impairment of threatening face processing is crucial for targeting more effective treatments. However, neuroimaging studies have not yet obtained robust conclusions. Through comprehensive literature search, twenty-one whole brain datasets were included in this meta-analysis. Using seed-based d-Mapping, in this voxel-based meta-analysis, we aimed to: 1) establish the most consistent brain dysfunctions related to threating face processing in schizophrenia; 2) address task-type heterogeneity in this impairment; 3) explore the effect of potential demographic or clinical moderator variables on this impairment...
November 15, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/29152847/a-case-study-in-identifying-targeted-patients-population-in-major-depressive-disorder-by-enhanced-enrichment-design
#20
Peter Zhang, Kevin Carroll, Mary Hobart, Carole Augustine, Gary Koch
Despite advances in clinical trial design, failure rates near 80% in phase 2 and 50% in phase 3 have recently been reported. The challenges to successful drug development are particularly acute in central nervous system trials such as for pain, schizophrenia, mania, and depression because high-placebo response rates lessen assay sensitivity, diminish estimated treatment effect sizes, and thereby decrease statistical power. This paper addresses the importance of rigorous patient selection in major depressive disorder trials through an enhanced enrichment paradigm...
November 19, 2017: Pharmaceutical Statistics
keyword
keyword
50210
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"